Eleven Bio Inc (EBIO) 3.94 $EBIO Eleven Biotherapeutics

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Eleven Bio Inc (EBIO) 3.94 $EBIO

Eleven Biotherapeutics (EBIO) Jumps: Stock Rises by 10.4%
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 7:00AM CDT
Eleven Biotherapeutics, Inc. (EBIO) was a big mover last session, as the company saw its shares rise over 10% on the day.
EBIO: 3.94 (-0.03), ANIP: 60.36 (-0.24)

Four Companies To Consider for Your Portfolio in August 2016
PR Newswire - Thu Jul 28, 11:45AM CDT
TechStockInsider.com Briefing: The Fed held its two-day meeting this week and after much deliberation, the decision has been made to leave rates where they are for right now. The guidance came after identifying that the current economic state is still relatively unstable while the outlook for the global economic unrest mainly rippling from Brexit have still some uncertainty. Despite this outlook on the economy, the decision actually has spurred interest in many stocks this morning with many "bottomed out" equities seeing price reversals including:
EVOK: 2.69 (+0.07), EBIO: 3.94 (-0.03), SPU: 13.18 (+1.01)

Biotech Ready for a Breakout
ACCESSWIRE - Thu Jul 28, 8:00AM CDT
LAS VEGAS, NV / ACCESSWIRE / July 28, 2016 / The Biotechnology sector is still struggling with a personal bear market, after dropping 40% from its high point in July 2015. While the overall market has strengthened and risen quite a bit from its lows, the biotechnology sector, as represented by IBB, an ETF tracking the Nasdaq Biotechnology Index, is still down 24% for the year. While the broader indexes have enjoyed some resurgence, the IBB has not been able to even come close to the 200 DMA level this year, and was 11% below it at the end of June.
EBIO: 3.94 (-0.03)

Eleven Biotherapeutics (EBIO) in Focus: Stock Rises 13%
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 7:25AM CDT
Eleven Biotherapeutics, Inc. (EBIO) moved big last session, as its shares jumped almost 13% on the day.
EBIO: 3.94 (-0.03), ANIP: 60.36 (-0.24)

Eleven Biotherapeutics Announces Effectiveness of Investigational New Drug Application for EBI-031
BusinessWire - Thu Jul 07, 3:18PM CDT
Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that the company's Investigational New Drug (IND) application for EBI-031, a humanized monoclonal antibody that potently binds interleukin-6 (IL-6) and inhibits all known forms of IL-6 cytokine signaling, for treatment of ocular diseases, has become effective. As a result of the achievement of this milestone, Eleven is entitled to receive a $22.5 million payment from F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (Roche) pursuant to the terms of its license agreement with Roche.
EBIO: 3.94 (-0.03)

Today's Market Movers - Eleven Biotherapeutics, Insys Therapeutics, Himax Technologies and Broadcom
ACCESSWIRE - Wed Jul 06, 8:00AM CDT
NEW YORK, NY / ACCESSWIRE / July 6, 2016 / U.S. markets stumbled Tuesday after posting the largest weekly gain of 2016 last week. Stocks fell as investors continued to sell off their riskier assets, i.e. stocks and commodities, for safe have assets following Britain's exit from the European Union. A flood of buying has seen the yield on the benchmark 10-year U.S. Treasury note hit a historical low of 1.370 percent. On Tuesday, the Dow Jones Industrial Average and the S&P 500 Index posted declines of 0.61 percent and 0.68 percent, respectively. Register with us now for your free membership and gain access to our daily Market Movers stock reports at: http://rdinvesting.com/
INSY: 15.95 (+0.30), EBIO: 3.94 (-0.03), HIMX: 8.88 (-0.07)

Biotechnology Stocks Under Review - Eleven Biotherapeutics, Relypsa, Galena Biopharma, and Amgen
PR Newswire - Mon Jun 20, 7:25AM CDT
On Friday, June 17, 2016, the NASDAQ Composite ended the trading session at 4,800.34, down 0.92%; the Dow Jones Industrial Average edged 0.33% lower, to finish at 17,675.16; and the S&P 500 closed at 2,071.22, down 0.33%. However, five out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Eleven Biotherapeutics Inc. (NASDAQ: EBIO), Relypsa Inc. (NASDAQ: RLYP), Galena Biopharma Inc. (NASDAQ: GALE), and Amgen Inc. (NASDAQ: AMGN). Learn more about these stocks by accessing their free trade alerts at:
EBIO: 3.94 (-0.03), RLYP: 31.87 (-0.07), AMGN: 174.05 (+2.02), GALE: 0.45 (+0.01)

Apple and Hanesbrands fall, LinkedIn and Symantec climb
AP - Mon Jun 13, 3:36PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Monday:
ARGS: 5.27 (+0.01), LNKD: 193.04 (+0.31), EBIO: 3.94 (-0.03), DUK: 85.69 (+0.10), HBI: 26.94 (+0.28), AAPL: 105.13 (+0.92), SYMC: 20.55 (+0.12)

Eleven Biotherapeutics Announces Signing of Exclusive License Agreement
BusinessWire - Mon Jun 13, 6:45AM CDT
--IND Submission for EBI-031 Announced Today
EBIO: 3.94 (-0.03)

Eleven Biotherapeutics Announces Investigational New Drug Application Submission to Initiate Clinical Trials of EBI-031 for Ocular Diseases
BusinessWire - Mon Jun 13, 6:30AM CDT
Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a Phase 1 clinical trial of EBI-031, a humanized monoclonal antibody that potently binds interleukin-6 (IL-6) and inhibits all known forms of IL-6 cytokine signaling, which may be effective for the treatment of ocular diseases such as diabetic macular edema and uveitis.
EBIO: 3.94 (-0.03)

Eleven Biotherapeutics Reports First Quarter 2016 Financial Results
BusinessWire - Thu May 05, 6:30AM CDT
Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today reported financial results for the first quarter ended March 31, 2016 and provided a review of recent business highlights.
EBIO: 3.94 (-0.03)

Four Top Stocks to Watch on Wednesday May 4th 2016
ACCESSWIRE - Wed May 04, 11:03AM CDT
MIAMI, FL / ACCESSWIRE / May 4, 2016 / Tech Stock Insider is issuing a report on four stocks to watch. EBIO, LCLP, XGTI, and MJNA have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks, subscribe to our newsletter at TechStockInsider.com.
EBIO: 3.94 (-0.03), XGTI: 0.44 (+0.02)

Genetic Stratification of Drug Response in IL-1 Implicated Eye Diseases
GlobeNewswire - Wed May 04, 7:00AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU), a life sciences company focused on developing and marketing proprietary genetic tests for chronic diseases and health-related conditions, announced today that Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, presented new data from post hoc analyses on the influence of Interleukin's IL-1 genetic patterns on response to isunakinra (EBI-005) in severe allergic conjunctivitis and severe dry eye study subjects. The data were presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Seattle, Washington.
EBIO: 3.94 (-0.03)

Eleven Biotherapeutics to Present Data at the ARVO 2016 Annual Meeting
BusinessWire - Fri Apr 29, 7:32AM CDT
Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that one oral presentation and three posters have been selected for presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2016 Annual Meeting taking place May 1-5, 2016, in Seattle, WA. The presentations include preclinical data for EBI-031, which is in development for diabetic macular edema and Phase 3 clinical data on isunakinra (EBI-005). Presentation abstracts can be found on the ARVO website at https://www.arvo.org/AM/Program/.
EBIO: 3.94 (-0.03)

Why Patents are the Lifeblood of Biotech Companies
ACCESSWIRE - Mon Apr 25, 8:36AM CDT
Protection of Intellectual Property Is At the Core of the Business for Biotechnology Firms
RPTP: 5.97 (+0.08), EBIO: 3.94 (-0.03), PTCT: 6.26 (+0.29), PETX: 7.60 (+0.01), ARRY: 3.81 (+0.07)

Trending Stocks To Have On Your Watch-list Friday (4/22/16)
ACCESSWIRE - Fri Apr 22, 11:21AM CDT
MIAMI, FL / ACCESSWIRE / April 22, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. COOL, NEOT, EBIO, and ARTX have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
COOL: 3.70 (+2.99), EBIO: 3.94 (-0.03), ARTX: 2.84 (+0.03), NEOT: 1.05 (unch), MJCO: 5.60 (-0.09)

4 Trending Small Cap Stocks Making Big Moves Today
ACCESSWIRE - Fri Apr 22, 9:12AM CDT
NEW YORK, NY / ACCESSWIRE / April 22, 2016 / The OTC Expert is issuing a report on four stocks that are trading with heavier than usual volume. EBIO, EXXI, SUNE and ATRS are on high volume watch. Continue reading to find out why these stocks are getting so much interest today. - If you want reports on the day's hottest stocks (NYSE/Nasdaq/OTC) subscribe to our newsletter at otc-expert.com.
EXXI: 0.13 (-0.01), EBIO: 3.94 (-0.03), SUNE: 0.34 (unch), ATRS: 1.01 (+0.01)

Penny Stocks to Watch on Thursday April 21
ACCESSWIRE - Thu Apr 21, 12:08PM CDT
MIAMI, FL / ACCESSWIRE / April 21, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. CBYL, EBIO, RJETQ, and AGHI have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the OTC, NASDAQ and NYSE subscribe to our newsletter at DailyStockReporter.com.
EBIO: 3.94 (-0.03), CBYL: 0.54 (unch)

Top Stocks on 4/20: Investors Are Considering These on Wednesday April 20th
ACCESSWIRE - Wed Apr 20, 11:57AM CDT
MIAMI, FL / ACCESSWIRE / April 20, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. EBIO, ASM, OCLS, and PBMD have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
PBMD: 0.93 (unch), EBIO: 3.94 (-0.03), OCLS: 4.00 (-0.29)

Top Penny Stocks: Four Small Cap Stocks You Should Be Watching On April 15th
ACCESSWIRE - Fri Apr 15, 11:09AM CDT
MIAMI, FL / ACCESSWIRE / April 15, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. EBIO, EXXI, TLOG, and RMHB have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the OTC, Nasdaq and NYSE subscribe to our newsletter at DailyStockReporter.com.
EXXI: 0.13 (-0.01), EBIO: 3.94 (-0.03), TLOG: 0.22 (-0.01)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 58

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 161

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 58

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Kinross Lawsuit Puts Round Mountain Claims Under Fire

Updated Category News Views 85

A mine can swallow a rosy forecast faster than any spreadsheet admits. That is the ugly center of the proposed securities class action involving Kinross Gold: not merely that production guidance came down, but the allegation that investors were sold too much confidence before the operational reality at Round Mountain Phase S surfaced. NYSE:KGC dropped from $27.62 on...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 162

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Charter Investigation Puts ACP Exit Claims Under Lens

Updated Category News Views 126

Charter’s ACP hangover has grown from an operating headache into a governance question. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether Charter Communications officers or directors breached fiduciary duties or otherwise broke state or federal law. That is not a finding of wrongdoing, and investors ought to keep that distinction...

Continue Reading
Fraud0-FouAnalytics Takes Aim at Legacy Ad Verification

Updated Category News Views 144

Digital ad measurement has spent years grading its own homework, and that little arrangement may finally be getting some daylight. fraud0 and FouAnalytics say their expanded partnership will give advertisers impression-level visibility into where ads actually rendered, whether apparent humans engaged with them, and where wasted Google Ads spend might be recoverable. The...

Continue Reading
Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 100

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
ASA’s 2026 Grants Push Dermatology Into New Terrain

Updated Category News Views 104

Thirteen Small Bets With Serious Human Stakes Skin science rarely gets the splashy headlines, yet it touches a staggering number of people and carries some very stubborn unanswered questions. American Skin Association’s 2026 grant class puts 13 awards across skin cancer and dermatologic disease, with a noticeable willingness to follow newer clinical terrain rather than...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 114

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring the Future of Palantir: A Promising Investment Opportunity

Updated Category News Views 200

The Rise of Palantir Technologies Palantir Technologies (NYSE: PLTR) has emerged as a notable force in the stock market, especially in the field of artificial intelligence (AI). Known for its complex data analytics platforms, Palantir was founded after the September 11 attacks to offer essential software solutions to federal intelligence agencies, assisting them in...

Continue Reading
Castellum, Inc. Achieves Record Revenue and Debt Reduction

Updated Category News Views 176

Castellum, Inc. Reports Impressive Q2 Financial Results Castellum, Inc. (NYSE-American: CTM), a prominent player in cybersecurity, electronic warfare, and software services directed towards the federal government, recently unveiled its financial results for the second quarter of 2025. The results showcase a record revenue performance, enhanced operational efficiencies,...

Continue Reading
Revolutionary Ultra H2 Wheelset by Superteam Wheels Debuts

Updated Category News Views 441

Introducing the Ultra H2 Wheelset Superteam Wheels, a notable name in the cycling industry, has taken a major step forward with the launch of their Ultra H2 Special Edition Wheelset. This new product is set to redefine the standards of performance wheels, appealing to cycling enthusiasts who seek the perfect blend of speed, reliability, and design. Advanced Technology at...

Continue Reading
Family Care Center's IOP Secures Three-Year CARF Accreditation

Updated Category News Views 200

Family Care Center Achieves Notable CARF Accreditation Family Care Center, a prominent national provider in behavioral health care, has recently announced a significant milestone: its intensive outpatient program (IOP) has earned a coveted three-year accreditation from the Commission on Accreditation of Rehabilitation Facilities (CARF). This accomplishment not only...

Continue Reading
Entergy Boosts Quarterly Dividend to Support Shareholders

Updated Category News Views 169

Entergy Announces Dividend Increase for Shareholders Entergy's board of directors has recently made a significant decision to enhance shareholder value. They declared a quarterly dividend payment of $0.64 per share, marking a notable increase of $0.04 per share. This increment reflects the company's ongoing commitment to rewarding its investors. Dividend Payment Schedule...

Continue Reading